Endovia Health Sciences (EDVA)
Market Price (9/21/2026): $0.25 | Market Cap: $93,701Sector: Health Care | Industry: Biotechnology
Endovia Health Sciences (EDVA)
Market Price (9/21/2026): $0.25Market Cap: $93,701Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -112% | Penny stockMkt Price is 0.2 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1236% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -96%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -11%, Rev Chg QQuarterly Revenue Change % is -203% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 293% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -973%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -973% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 61% Key risksEDVA key risks include [1] severe financial distress that has created substantial doubt about its ability to continue as a going concern and [2] a critical dependence on external, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -77%, 3Y Excs Rtn is -112% |
| Penny stockMkt Price is 0.2 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1236% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -96%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -11%, Rev Chg QQuarterly Revenue Change % is -203% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 293% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -973%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -973% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 61% |
| Key risksEDVA key risks include [1] severe financial distress that has created substantial doubt about its ability to continue as a going concern and [2] a critical dependence on external, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 9/17/2026
Endovia Health Sciences (EDVA) stock has lost about 40% since it went public on 8/25/2026 because of the following key factors:
1. Persistent Weak Financial Fundamentals and Historical Performance. The company's transition to a public entity on August 24, 2026, was preceded by and continues to be impacted by significantly weak financial results. Endovia Health Sciences reported a substantial decrease in revenue of 90.9% to $73K in fiscal year 2025. Furthermore, the company incurred a net loss of approximately $25.23 million as of September 7, 2026, with diluted earnings per share of -$11.97 for fiscal year 2025. This financial distress is compounded by persistent cash burn and negative equity of -$15.7 million. This weak financial position significantly undermines investor confidence in the company's prospects.
2. Elevated Financial Distress Risk and Poor Liquidity. Endovia Health Sciences exhibits a high financial distress risk, scoring an "elevated" 54 out of 100 as of September 7, 2026. This is further evidenced by a very low current ratio, ranging from 0.04 to 0.05, which indicates extremely poor short-term liquidity and raises concerns about the company's ability to meet its immediate financial obligations.
Show more
Endovia Health Sciences (EDVA) stock has lost about 40% since it went public on 8/25/2026 because of the following key factors:
1. Persistent Weak Financial Fundamentals and Historical Performance. The company's transition to a public entity on August 24, 2026, was preceded by and continues to be impacted by significantly weak financial results. Endovia Health Sciences reported a substantial decrease in revenue of 90.9% to $73K in fiscal year 2025. Furthermore, the company incurred a net loss of approximately $25.23 million as of September 7, 2026, with diluted earnings per share of -$11.97 for fiscal year 2025. This financial distress is compounded by persistent cash burn and negative equity of -$15.7 million. This weak financial position significantly undermines investor confidence in the company's prospects.
2. Elevated Financial Distress Risk and Poor Liquidity. Endovia Health Sciences exhibits a high financial distress risk, scoring an "elevated" 54 out of 100 as of September 7, 2026. This is further evidenced by a very low current ratio, ranging from 0.04 to 0.05, which indicates extremely poor short-term liquidity and raises concerns about the company's ability to meet its immediate financial obligations.
Show more
Updated on 9/17/2026
Endovia Health Sciences (EDVA) stock has lost about 40% since it went public on 8/25/2026 because of the following key factors:
1. Persistent Weak Financial Fundamentals and Historical Performance. The company's transition to a public entity on August 24, 2026, was preceded by and continues to be impacted by significantly weak financial results. Endovia Health Sciences reported a substantial decrease in revenue of 90.9% to $73K in fiscal year 2025. Furthermore, the company incurred a net loss of approximately $25.23 million as of September 7, 2026, with diluted earnings per share of -$11.97 for fiscal year 2025. This financial distress is compounded by persistent cash burn and negative equity of -$15.7 million. This weak financial position significantly undermines investor confidence in the company's prospects.
2. Elevated Financial Distress Risk and Poor Liquidity. Endovia Health Sciences exhibits a high financial distress risk, scoring an "elevated" 54 out of 100 as of September 7, 2026. This is further evidenced by a very low current ratio, ranging from 0.04 to 0.05, which indicates extremely poor short-term liquidity and raises concerns about the company's ability to meet its immediate financial obligations.
3. Strategic Pivot and Associated Execution Risk. The company underwent a significant strategic transformation, rebranding from Splash Beverage Group to Endovia Health Sciences and shifting its core business from legacy beverages to a cannabinoid-based health sciences platform, effective with its NYSE American listing on August 24, 2026. This pivot into the complex and highly regulated pharmaceutical industry, which includes FDA-regulated human and veterinary therapeutics, presents substantial execution risk, especially for a company with a history of weak financial performance. Investors may be hesitant to embrace this new direction without demonstrated progress and financial stability.
4. Significant Share Dilution Prior to Public Listing. While not directly tied to the period since the IPO, the company experienced substantial share dilution in the year leading up to its public listing. Total shares outstanding increased by 224.85% within the last year, and some sources indicate an increase of 1096.7% over the past year. This significant expansion of the share base before entering the public market inherently reduces the per-share value and can contribute to negative investor sentiment regarding future capital management.
Show less
Endovia Health Sciences (EDVA) stock has lost about 40% since it went public on 8/25/2026 because of the following key factors:
1. Persistent Weak Financial Fundamentals and Historical Performance. The company's transition to a public entity on August 24, 2026, was preceded by and continues to be impacted by significantly weak financial results. Endovia Health Sciences reported a substantial decrease in revenue of 90.9% to $73K in fiscal year 2025. Furthermore, the company incurred a net loss of approximately $25.23 million as of September 7, 2026, with diluted earnings per share of -$11.97 for fiscal year 2025. This financial distress is compounded by persistent cash burn and negative equity of -$15.7 million. This weak financial position significantly undermines investor confidence in the company's prospects.
2. Elevated Financial Distress Risk and Poor Liquidity. Endovia Health Sciences exhibits a high financial distress risk, scoring an "elevated" 54 out of 100 as of September 7, 2026. This is further evidenced by a very low current ratio, ranging from 0.04 to 0.05, which indicates extremely poor short-term liquidity and raises concerns about the company's ability to meet its immediate financial obligations.
3. Strategic Pivot and Associated Execution Risk. The company underwent a significant strategic transformation, rebranding from Splash Beverage Group to Endovia Health Sciences and shifting its core business from legacy beverages to a cannabinoid-based health sciences platform, effective with its NYSE American listing on August 24, 2026. This pivot into the complex and highly regulated pharmaceutical industry, which includes FDA-regulated human and veterinary therapeutics, presents substantial execution risk, especially for a company with a history of weak financial performance. Investors may be hesitant to embrace this new direction without demonstrated progress and financial stability.
4. Significant Share Dilution Prior to Public Listing. While not directly tied to the period since the IPO, the company experienced substantial share dilution in the year leading up to its public listing. Total shares outstanding increased by 224.85% within the last year, and some sources indicate an increase of 1096.7% over the past year. This significant expansion of the share base before entering the public market inherently reduces the per-share value and can contribute to negative investor sentiment regarding future capital management.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| EDVA | ||
| Market (SPY) | 0.9% | 12.0% |
| Sector (XLV) | 12.7% | 24.6% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| EDVA | ||
| Market (SPY) | 11.6% | 12.0% |
| Sector (XLV) | 5.5% | 24.6% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| EDVA | ||
| Market (SPY) | 19.4% | 12.0% |
| Sector (XLV) | 24.1% | 24.6% |
Fundamental Drivers
nullnull
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| EDVA | ||
| Market (SPY) | 75.6% | 12.0% |
| Sector (XLV) | 32.3% | 24.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EDVA Return | - | - | - | - | - | -36% | -36% |
| Peers Return | -7% | 32% | 41% | -1% | 13% | 18% | 127% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| EDVA Win Rate | - | - | - | - | - | 0% | |
| Peers Win Rate | 42% | 67% | 58% | 50% | 83% | 64% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| EDVA Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -27% | -19% | -12% | -23% | -29% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
EDVA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
EDVA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Endovia Health Sciences (EDVA)
Endovia Health Sciences (EDVA), operating as Splash Beverage Group, Inc., is a beverage company engaged in the manufacturing, distribution, marketing, and sale of a diverse portfolio of drinks. The company's operations extend beyond traditional channels to include online retail, where it sells beverages and groceries through its dedicated e-commerce platform.
Its product lineup encompasses a variety of alcoholic beverages, including SALT Naturally Flavored Tequila, Copa di Vino wine, and Pulpoloco Sangria. In the non-alcoholic sector, EDVA offers TapouT Performance, an isotonic sports drink formulated for hydration and recovery. A key service is also its online storefront, qplash.com, which facilitates the direct sale of its beverages and other grocery items to consumers.
Endovia Health Sciences primarily serves the United States market. Its wide-ranging product offerings cater to multiple customer segments, including adults interested in spirits and wines, athletes and active individuals seeking performance beverages, and general consumers desiring convenient online access to a selection of beverages and groceries.
AI Analysis | Feedback
A small-cap Constellation Brands.
A diversified beverage producer, like a startup Boston Beer Company.
AI Analysis | Feedback
- SALT Naturally Flavored Tequila: Flavored tequilas.
- TapouT Performance: A hydration and recovery isotonic sport drink.
- Copa di Vino: Wine products.
- Pulpoloco Sangria: Sangria products.
- qplash.com: An online platform for selling beverages and groceries.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
The key risks for Endovia Health Sciences (symbol: EDVA) are primarily related to its significant financial distress, the inherent uncertainties of drug development and regulatory approval in its new cannabinoid health sciences focus, and its heavy reliance on external capital to fund operations and product development.
- Financial Distress and Going Concern Issues: Endovia Health Sciences is facing severe financial challenges, including recurring operating losses and negative cash flows. In 2025, the company reported a net loss of $25.3 million. As of June 30, 2026, its cash and cash equivalents amounted to only $242,702, which is deemed insufficient to cover 12 months of operations. Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to its working capital deficit and liquidity risks. The company's revenue has sharply declined, and its financial statements indicate severe stress with large net losses and negative equity.
- Regulatory Risks and Uncertainty in Cannabinoid Drug Development: Endovia Health Sciences has transitioned its business focus to a cannabinoid health sciences platform, concentrating on pharmaceutical, wellness, and veterinary cannabinoid products. This pivot involves navigating complex FDA regulatory pathways for the development and commercialization of its cannabinoid-based therapies, such as CannEpil® for drug-resistant epilepsy and veterinary applications. The process of obtaining FDA approval for new drugs is lengthy, expensive, and uncertain, posing significant risks regarding the company's ability to complete necessary studies and secure regulatory authorization for its products.
- Dependence on External Capital and Potential for Dilution: The company is highly reliant on raising external capital to fund its ongoing operations and product development initiatives, particularly for its CannEpil® program, which requires at least $2 million over the next 12 months. Endovia Health Sciences is utilizing an equity line of credit (ELOC) to secure up to $30.8 million in gross proceeds; however, the actual amount received is contingent on share sales and market price. This dependence on external financing, including dilutive equity arrangements, poses a significant risk for existing shareholders due to potential share dilution. The company's forward-looking statements explicitly highlight risks related to its ability to raise capital and meet contractual obligations.
AI Analysis | Feedback
Here are clear emerging threats for Splash Beverage Group, Inc. (EDVA):
- The accelerating "better-for-you" trend across all beverage categories: Consumers are increasingly demanding natural ingredients, lower sugar content, and functional benefits from their drinks. This trend has led to a proliferation of new brands specifically targeting health-conscious consumers. Splash Beverage Group's existing portfolio, particularly flavored tequilas, wines, and sangrias, may face challenges if they are not perceived as aligning with these evolving health and wellness preferences, potentially making them less competitive against newer, more agile brands built around these principles.
- The growing "sober curious" movement and the rise of sophisticated non-alcoholic alternatives: There is a discernible and accelerating cultural shift, particularly among younger demographics, towards reducing or abstaining from alcohol consumption. This has fueled a booming market for high-quality non-alcoholic spirits, wines, beers, and ready-to-drink options. As a company with a significant portion of its portfolio in alcoholic beverages (flavored tequilas, wine, sangria), this movement represents a direct threat to the demand for their core products by potentially shrinking the overall market for traditional alcoholic drinks and offering increasingly appealing substitutes.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Share Issuance
- The company plans to issue approximately 54.4 million shares of common and preferred stock as part of the Medterra CBD, LLC acquisition, valued at $37.6 million.
- In 2025, shareholders approved an increase in authorized common shares to 400 million.
- Debt conversions and asset acquisitions in 2025 involved share issuances to reshape the balance sheet.
Inbound Investments
- Endovia Health Sciences (formerly Splash Beverage Group) has faced severe liquidity challenges, indicating a dependence on new financing for its operations.
- New funding and capital raises were undertaken in 2024 to support growth plans.
Outbound Investments
- The company is pursuing the acquisition of Medterra CBD, LLC, valued at $37.6 million, which includes the repayment of approximately $10.4 million of Medterra debt and additional cash for Medterra investors' taxes.
- Splash Beverage Group invested in Avicanna, a cannabinoid biopharmaceutical platform, as part of its strategic shift towards cannabinoid healthcare.
- A previously planned $20 million deal for Costa Rica water assets was rescinded prior to December 31, 2025.
Capital Expenditures
- The company estimates requiring at least $2 million in working capital, an additional $500,000 to develop its Chispo Tequila brand, and approximately $3 million for broader operating needs to revive beverage revenues.
- Operations effectively stalled after early 2025 due to a lack of capital, suggesting minimal capital expenditures during that period.
Peer Outperformance in Biotechnology
nullShare of Biotechnology constituents that EDVA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
—
insufficient peer history
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is EDVA's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology ← | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 27.37 |
| Mkt Cap | 129.0 |
| Rev LTM | 1 |
| Op Inc LTM | -20 |
| FCF LTM | -45 |
| FCF 3Y Avg | 973 |
| CFO LTM | -42 |
| CFO 3Y Avg | 1,194 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -42.8% |
| Rev Chg 3Y Avg | -0.4% |
| Rev Chg Q | -95.3% |
| QoQ Delta Rev Chg LTM | -42.1% |
| Op Inc Chg LTM | 1,266.6% |
| Op Inc Chg 3Y Avg | 411.3% |
| Op Mgn LTM | -607.9% |
| Op Mgn 3Y Avg | -227.2% |
| QoQ Delta Op Mgn LTM | -514.8% |
| CFO/Rev LTM | -522.2% |
| CFO/Rev 3Y Avg | -174.4% |
| FCF/Rev LTM | -522.2% |
| FCF/Rev 3Y Avg | -176.4% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| E-Commerce | 1 | 14 | 13 | 7 | 2 |
| Splash Beverage | 0 | 5 | 5 | 4 | 0 |
| Total | 1 | 19 | 18 | 11 | 2 |
| $ Mil | 2024 | 2023 | 2022 |
|---|---|---|---|
| E-Commerce | -0 | -2 | 5 |
| Splash Beverage | -9 | -14 | -2 |
| Contracted services | -2 | ||
| Non-cash share-based compensation | -7 | ||
| Other general and administrative | -11 | ||
| Salary and wages | -4 | ||
| Total | -9 | -15 | -21 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Splash Beverage | 2 | 9 | 15 | 15 | 8 |
| Assets of discontinued operations | 1 | 0 | 0 | ||
| E-Commerce | 0 | 1 | 3 | 1 | 1 |
| Total | 3 | 10 | 17 | 16 | 9 |
Price Behavior
null
EDVA Betas & Captures as of 8/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -8.47 | -5.52 | -2.55 | 2.22 | 1.98 | -3.39 |
| Up Beta | 0.49 | -0.55 | -0.50 | 0.48 | 0.56 | -0.39 |
| Down Beta | 1.99 | -1.18 | -0.82 | 0.84 | 0.84 | -0.65 |
| Up Capture | -357% | -171% | -100% | -38% | -17% | -2% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 0 | 0 | 0 | 0 | 0 | 0 |
| Down Capture | 154% | 59% | 31% | 18% | 11% | 6% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 4 | 4 | 4 | 4 | 4 | 4 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDVA | |
|---|---|---|---|---|
| EDVA | -41.3% | 90.5% | -8.16 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 24.6% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 12.0% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 11.4% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -24.4% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | 56.0% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | -7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDVA | |
|---|---|---|---|---|
| EDVA | -10.1% | 90.5% | -8.16 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 24.6% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 12.0% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 11.4% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | -24.4% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 56.0% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | -7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDVA | |
|---|---|---|---|---|
| EDVA | -5.2% | 90.5% | -8.16 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 24.6% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 12.0% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 11.4% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | -24.4% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 56.0% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | -7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2024 | 07/11/2025 | 10-K |
| 09/30/2024 | 11/15/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 06/06/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2024 | 07/11/2025 | 10-K |
| 09/30/2024 | 11/15/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 06/06/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| 12/31/2020 | 03/08/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/13/2020 | 10-Q |
| 12/31/2019 | 03/27/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
| 06/30/2019 | 08/14/2019 | 10-Q |
| 03/31/2019 | 05/21/2019 | 10-Q |
| 12/31/2018 | 03/29/2019 | 10-K |
| 09/30/2018 | 11/14/2018 | 10-Q |
| 06/30/2018 | 08/20/2018 | 10-Q |
| 03/31/2018 | 05/15/2018 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 9/20/2026